Evidence map›Paper›PMID 42763399›Full record

Observational studyLipids in health and disease2026

Real-world use of bempedoic acid for hypercholesterolaemia: a German multicentre, retrospective, cohort study.

Linus Haberbosch, Andrea Baessler, Ulrike de Ruiter, David Sinning, Julius L Katzmann, Stephanie Könemann, Ulrike Schatz, Knut Mai, Ursula Kassner, Thomas Bobbert

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Linus HaberboschDepartment of Endocrinology and Metabolism, Charité-Universitätsmedizin Berlin,Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), Charitéplatz 1, Berlin, 10117, Germany.
Andrea BaesslerDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Ulrike de RuiterDialysis and Lipid Centre Nordrhein, Essen, Germany.
David SinningATOS MVZ KANT KARDIO, Berlin, Germany.
Julius L KatzmannDepartment of Cardiology, University Hospital Leipzig, Leipzig, Germany.
Stephanie KönemannDepartment of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.
Ulrike SchatzDepartment of Internal Medicine III, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
Knut MaiDepartment of Endocrinology and Metabolism, Charité-Universitätsmedizin Berlin,Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), Charitéplatz 1, Berlin, 10117, Germany.
Ursula KassnerDepartment of Endocrinology and Metabolism, Charité-Universitätsmedizin Berlin,Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), Charitéplatz 1, Berlin, 10117, Germany.
Thomas BobbertDepartment of Endocrinology and Metabolism, Charité-Universitätsmedizin Berlin,Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), Charitéplatz 1, Berlin, 10117, Germany. thomas.bobbert@charite.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDyslipidaemia remains a leading cause of death in Germany despite an improving therapeutic landscape, with many patients not achieving guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals. Bempedoic acid, an adenosine triphosphate citrate lyase inhibitor, is a recent addition to the therapeutic landscape with proven efficacy in randomised controlled trials; however, its use varies between centres. We aimed to assess the short-term, real-world effectiveness of bempedoic acid in lowering LDL-C levels in patients in Germany.

methodsThis retrospective, observational study was conducted using data from patients with primary hypercholesterolaemia or mixed dyslipidaemia, collected before and approximately 3 months after initiating bempedoic acid in 7 specialised lipid outpatient clinics in Germany.

resultsData were analysed from a total of 641 patients, with a mean age (standard deviation [SD]) of 63.2 (11.3) years. The addition of bempedoic acid significantly reduced LDL-C levels from a mean of 133.6 mg/dL at baseline to 101.8 mg/dL after 3 months (p < 0.001). The mean within-patient LDL-C reduction was 31.8 mg/dL and the mean patient-level percentage change was -17.5%. Mean patient-level changes were -4.9% for HDL-C and -12.0% for total cholesterol; triglycerides did not change significantly. At 3 months, patients not receiving any lipid-lowering therapy (LLT) other than bempedoic acid had a mean patient-level LDL-C reduction of 27.1%; corresponding mean reductions were 23.7% with ezetimibe, 20.3% with PCSK9 inhibitor therapy, 9.0% with statin therapy and 6.1% with statin plus ezetimibe. Suspected adverse events were documented in 218/641 patients (34.0%), and 171/641 (26.7%) had discontinued bempedoic acid by follow-up. Myalgia was the most commonly reported adverse event in patients discontinuing treatment (75 cases).

conclusionsFindings from this real-world, multicentre study conducted in Germany show that bempedoic acid may present an effective treatment option for patients with hypercholesterolaemia who are already receiving LLT, in addition to being an effective option for patients not receiving/tolerating other LLTs. The magnitude of LDL-C reduction differed across background treatment strategies, while suspected adverse events and treatment discontinuation were common in this specialist-care cohort.

Indexed as

Anticholesteremic AgentsDicarboxylic AcidsFatty AcidsHypercholesterolemiaAgedCholesterol, LDLEzetimibeFemaleGermanyHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedProprotein Convertase 9Retrospective Studies8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidAnticholesteremic AgentsCholesterol, LDLDicarboxylic AcidsEzetimibeFatty AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Bempedoic acidCardiovascular riskDyslipidaemiaHypercholesterolaemiaLipid lowering therapyLow-density lipoprotein cholesterol

Identifiers

PMID42763399
PMCPMC13589388

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.